Karen Smith

Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA.

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.

Celator Pharmaceuticals, Inc. engages in the research and development of biopharmaceutical products. The company was founded by Lawrence David Mayer, and Marcel B. Bally in 1999 and is headquartered in Ewing, NJ.

Boron Molecular Ltd. manufactures fine chemicals. Its products include biaryls, boronic acid esters and acids, catalyst, cubanes, diborons, energy storage, halides, polymer, raft agents, and trifluoroborates. The company was founded in 2001 and is headquartered in Noble Park, Australia.

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.

Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 2005 and is headquartered in Copenhagen, Denmark.

Humanetics Corp. engages in development and commercialization of bioactive compounds. Its products include radiation modulators, mechanism of action, safety and toxicology, and pharmacokinetics. It focuses on oncology, medical imaging, and medical countermeasures. The company was founded by Ronald J. Zenk in 1988 and is headquartered in Edina, MN.

Part of AstraZeneca PLC, AstraZeneca LP is a pharmaceutical company that focuses on developing and commercializing prescription drugs for various therapeutic areas. The private company is based in Wilmington, DE.

Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company, which engages in the development of allogeneic hematopoietic stem cell transplantation. The company was founded by Suzanne Ildstad on February 15, 2002 and is headquartered in Wellesley, MA.

Medeor Therapeutics, Inc. engages in medical industry. It provides services which are dedicated to the discovery, development, and commercialization of transformative and personalized cellular therapeutics. The company was founded by Samuel Strober, Edgar Engleman, Robert Lowsky, and Chih Ping in 2012 and is headquartered in South San Francisco, CA.

Novosteo, Inc. develops drug to reduce complications from a broken bone. The company was founded by Stewart A. Low and Philips S. Low in 2017 and is headquartered in West Lafayette, IN.

Mariana Oncology, Inc., also known as Curie Therapeutics, is a radiopharmaceuticals company that specializes in developing safe and effective targeted radiopharmaceuticals for cancer treatment. The company is based in Woburn, MA and was founded by Simon Read, who has been the CEO since incorporation. The company's radiopharmaceuticals are designed to deliver alpha and beta-emitting radionuclide payloads to carefully selected biological targets.

Capstan Therapeutics, Inc. is a biotechnology company that develops targeted in vivo RNA technologies to multiply therapeutic possibilities for patients. Capstan Therapeutics is based in San Diego, CA. The company's platform technology, tLNPs, delivers payloads capable of reprogramming specific cell types in vivo, including gene editing tools. The company aims to generate transformative therapies for autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. The company was founded in 2022 by Haig Aghajanian, and the CEO is Laura K. Shawver.